Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688193'
s ROE % Range Over the Past 10 Years
Min: -22.41 Med: 1.83 Max: 33.57
Current: 1.52
During the past 8 years, Shanghai Rendu Biotechnology Co's highest ROE % was 33.57%. The lowest was -22.41%. And the median was 1.83%.
SHSE:688193's ROE % is ranked better than 57.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.32
vs SHSE:688193: 1.52
Shanghai Rendu Biotechnology Co (SHSE:688193) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Shanghai Rendu Biotechnology Co ROE % Related Terms
Shanghai Rendu Biotechnology Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Shanghai Rendu Biotechnology Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Rendu Biotechnology Co ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Rendu Biotechnology Co's ROE % distribution charts can be found below:
* The bar in red indicates where Shanghai Rendu Biotechnology Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Shanghai Rendu Biotechnology Co (SHSE:688193) has a ROE % of 2.18% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai Rendu Biotechnology Co and its competitors. This is 19% above median its historical median of 1.83. According to the industry distribution chart, Shanghai Rendu Biotechnology Co ranks #85 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 42.5%.
Is Shanghai Rendu Biotechnology Co's ROE % too high?
Shanghai Rendu Biotechnology Co's current ROE % of 2.18% is 19% above median its 10-year median of 1.83. Based on the distribution chart, Shanghai Rendu Biotechnology Co ranks #85 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shanghai Rendu Biotechnology Co has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rendu Biotechnology Co's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shanghai Rendu Biotechnology Co ranks #85 out of 200 companies for ROE %. This puts Shanghai Rendu Biotechnology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai Rendu Biotechnology Co and its competitors. Shanghai Rendu Biotechnology Co's current ROE % is 2.18%, which is 19% above median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rendu Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co (SHSE:688193) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥35.09, compared to a current price of ¥41.00 — trading 16.8% above its estimated fair value. The current ROE % is 2.18%, which is 19% above median its 10-year median of 1.83. Shanghai Rendu Biotechnology Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shanghai Rendu Biotechnology Co (SHSE:688193), the current ROE % is 2.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Rendu Biotechnology Co (SHSE:688193) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co stock appears to be overvalued.
The current stock price of ¥41.00 is trading 16.8% above its estimated GF Value™ of ¥35.09.
GuruFocus considers Shanghai Rendu Biotechnology Co to be Modestly Overvalued.
Key valuation signals for SHSE:688193:
ROE %: 2.18% (19% above median its 10-year median of 1.83)
GF Value™: ¥35.09 vs. price of ¥41.00 (16.8% above fair value)
No single metric tells the full story. See the SHSE:688193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Rendu Biotechnology Co Business Description
Shanghai Rendu Biotechnology Co Ltd provides solutions for accurate diagnosis, effective prevention and control, as well as personalized diagnosis and treatment of pathogens in the areas of reproduction, respiration, digestion, blood, food, and environmental safety.
61GF Score
Get the complete analysis for SHSE:688193
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688193 has been successfully added to your 
